Moderna has opened an mRNA facility in Oxfordshire (pictured), but many pharma companies are pulling out of the UK

Image: Moderna

14 October 2025FeaturesEuropeTim Belcher

As investment in UK life sciences wanes, is the sector in trouble?

As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

IP in the deal room: The risks that bite before, during and after closing

7 May 2026 Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.

Europe

Five generations at work: How teams are bridging the gap

6 May 2026 Panellists at INTA share how workplaces can bridge generational divides and why those differences may be a team’s biggest strengths.

Europe

WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA

5 May 2026 John Ward, vice president and associate general counsel of trademarks at Moderna, chats with Tom Phillips at INTA 2026.